SciSparc Ltd. SPRC
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
SciSparc Ltd. (SPRC) is a healthcare company listed in the US with a market value of about $869843. In fiscal year 2024 it had revenue of $1M and net income of -$6M, a net margin of -481.2%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -100%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 74% below the current price.
About SciSparc
SciSparc is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 1 of the last 10 years in our data.
Score: 1.0 / 5
Checks passed
- 5-year EPS growth above 10% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $3M | $1M | — | — | — | — | — | — | — |
| Net income | -$6M | -$5M | -$3M | -$6M | -$4M | -$5M | -$9M | -$6M | -$2M | $3M |
| Free cash flow | — | — | -$8M | -$5M | — | -$5M | -$7M | -$5M | -$1M | -$1M |
| EPS (diluted) | $-2.55 | $-2.08 | $-1.05 | $-2.35 | $-1.44 | $-1.90 | $-3.63 | $-2.53 | $-0.81 | $1.03 |
| Net margin | -481.2% | -177.9% | -192.4% | — | — | — | — | — | — | — |
| ROIC | -89.6% | -70.7% | -101.5% | -56.0% | -181.9% | -23180.9% | -3888.0% | -54.2% | -275.7% | 175.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is SciSparc stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 74% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does SciSparc pay a dividend?
Not currently.
Is SciSparc a good stock to buy?
We do not give buy or sell advice. SciSparc scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.